WJA
TEVA icon

Williams Jones & Associates’s Teva Pharmaceuticals TEVA Stock Holding History

Williams Jones & Associates’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-48,360
Closed -$758K – 414
2019
Q1 		$758K Buy
+48,360
New +$853K 0.02% 227
2016
Q2 		– Sell
-1,317
Closed -$70K – 419
2016
Q1 		$70K Buy
+1,317
New +$77.3K ﹤0.01% 335
2013
Q4 		– Sell
-118,360
Closed -$4.47M – 375
2013
Q3 		$4.47M Sell
118,360
-3,491
-3% -$136K 0.23% 91
2013
Q2 		$4.78M Buy
+121,851
New +$4.75M 0.24% 96

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Williams Jones & Associates's TEVA Position: Q2 2019 in Review

Williams Jones & Associates sold out of Teva Pharmaceuticals (TEVA) in Q2 2019, closing a stake of 48,360 shares — an estimated $758K sold.

Williams Jones & Associates first reported a position in TEVA in Q2 2013 and held it in 4 quarters. The position peaked at $4.78M in Q2 2013. 452 funds tracked by Wall St. Rank hold TEVA as of Q2 2019.

  • Williams Jones & Associates reported no remaining Teva Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Williams Jones & Associates sold 48,360 Teva Pharmaceuticals shares in Q2 2019, an estimated $758K.
  • Williams Jones & Associates first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 4 quarters.
  • Williams Jones & Associates's Teva Pharmaceuticals position peaked at $4.78M in Q2 2013.
  • 452 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2019.

Based on Williams Jones & Associates's 13F filing for Q2 2019, filed 14 Aug 2019.